Deutsche Bank Cuts Spyre Therapeutics Price Target to $123, Keeps Buy Rating
Deutsche Bank lowered its price target for Spyre Therapeutics to $123 from $127 while maintaining a Buy rating.
Deutsche Bank lowered its price target for Spyre Therapeutics to $123 from $127 while maintaining a Buy rating.